ASND · Ascendis Pharma
AI read · Good for ASND
The AI's read
Ascendis posted €339 million in Q2 revenue, with product revenue €315 million and Yorvipath at €252 million, hitting blockbuster status. That is clear commercial traction for a once-commercial-stage biotech. The market actually trimmed the stock about 2.3% after the print, so upside hasn't been fully priced and RSI is a comfortable 63.6. The selloff looks like profit-taking or caution, not a conviction reject. We lean bullish. Fast revenue growth, a €5bn 2030 ambition, and €812m cash create asymmetric upside if launches keep compounding.